Evidence map›Paper›PMID 38017580›Full record

ArticleMolecular neurodegeneration2023

Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants.

Karen Y He, Ekaterina A Khramtsova, Alfredo Cabrera-Socorro, Yanfei Zhang, Shuwei Li, Brice A J Sarver, Bart Smets, Qingqin S Li, Louis De Muynck, Antonio R Parrado and 2 more

Abstract readLetter
In one paragraph

Article in Molecular neurodegeneration, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. ApoE3 Christchurch and tau interaction as a protective mechanism against Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Multifaceted roles of APOE in Alzheimer disease.Nature reviews. Neurology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Karen Y He *Population Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA. KHe2@ITS.JNJ.com.ORCID 0000-0002-8686-7697
Ekaterina A Khramtsova *Population Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA. eakhram@gmail.com.
Alfredo Cabrera-SocorroNeuroscience Therapeutic Area, Janssen R&D, Beerse, Belgium.
Yanfei ZhangPopulation Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA.
Shuwei LiPopulation Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA.
Brice A J SarverPopulation Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA.
Bart SmetsNeuroscience Data Science, Janssen R&D, Beerse, Belgium.
Qingqin S LiNeuroscience Data Science, Janssen R&D, Titusville, NJ, USA.
Louis De MuynckNeuroscience Therapeutic Area, Janssen R&D, Beerse, Belgium.
Antonio R ParradoPopulation Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA.
Simon LovestoneNeuroscience Therapeutic Area, Janssen R&D, Beerse, Belgium.
Mary Helen BlackPopulation Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA.

Funding

Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseBiological Specimen BanksApolipoprotein E4Apolipoproteins EGenotypeHumansUnited KingdomApolipoprotein E4Apolipoproteins EAlzheimer’s diseaseAPOE-Christchurch variantRare variants

Identifiers

PMID38017580
PMCPMC10685495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.